Barclays’s DiaMedica Therapeutics DMAC Stock Holding History

Barclays’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$152K	Buy	18,353 +5,208	+40%	+$36.4K	﹤0.01%	4121
2026 Q2	$92.5K	Buy	13,145 +6,658	+103%	+$40.9K	﹤0.01%	4071
2026 Q1	$43.9K	Sell	6,487 -46,424	-88%	-$368K	﹤0.01%	4365
2025 Q4	$421K	Buy	52,911 +7,471	+16%	+$55.9K	﹤0.01%	3935
2025 Q3	$312K	Sell	45,440 -3,333	-7%	-$18.1K	﹤0.01%	4070
2025 Q2	$190K	Buy	48,773 +30,503	+167%	+$119K	﹤0.01%	4313
2025 Q1	$69.2K	Sell	18,270 -9,456	-34%	-$54.1K	﹤0.01%	4521
2024 Q4	$151K	Buy	+27,726	New	+$131K	﹤0.01%	4430
2021 Q4	–	Sell	-4,616	Closed	-$19K	–	4231
2021 Q3	$19K	Buy	4,616 +3,208	+228%	+$12.3K	﹤0.01%	4404
2021 Q2	$6K	Sell	1,408 -2,004	-59%	-$16.4K	﹤0.01%	4728
2021 Q1	$31K	Buy	+3,412	New	+$31.9K	﹤0.01%	4292

Other funds holding DMAC

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Members Wealth Media, Pennsylvania $200M AUM 9.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Meridian Wealth Management Lexington, Kentucky $3.35B AUM 30.28% 1-Year Est. Return

Catalyst Financial Partners Boston, Massachusetts $1.07B AUM 26.85% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Barclays's DMAC Position: Q3 2026 in Review

Barclays increased its DiaMedica Therapeutics (DMAC) stake by 40% in Q3 2026, buying an estimated $36.4K and bringing the position to 18,353 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #4121.

Barclays first reported a position in DMAC in Q1 2021 and has held it in 11 quarters since. The position peaked at $421K in Q4 2025. 39 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

Barclays held 18,353 shares of DiaMedica Therapeutics worth $152K as of Q3 2026.
Barclays bought 5,208 DiaMedica Therapeutics shares in Q3 2026, an estimated $36.4K.
DiaMedica Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4121 holding.
Barclays first reported a position in DiaMedica Therapeutics in Q1 2021 and has held it in 11 quarters since.
Barclays's DiaMedica Therapeutics position peaked at $421K in Q4 2025.
39 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.